QQ客服 官方微博 反馈留言

	Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients
	Ni Jun; Qu Jiazhi; Yao Ming; Zhang Zhijun; Zhong Xihua; Cui Liying
	2017
卷号	8期号:4页码:341-346
关键词	Acute ischemic stroke Acute stroke therapy Protocols Registry study
ISSN号	1868-4483
DOI	10.1007/s12975-017-0527-5
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6367649
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Ni Jun,Qu Jiazhi,Yao Ming,et al. Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients[J],2017,8(4):341-346.
APA	Ni Jun,Qu Jiazhi,Yao Ming,Zhang Zhijun,Zhong Xihua,&Cui Liying.(2017).Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients.,8(4),341-346.
MLA	Ni Jun,et al."Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients".8.4(2017):341-346.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。